We could not find any results for:
Make sure your spelling is correct or try broadening your search.
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS),Β a clinical-stage precision oncology company developing...
Peer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant...
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are...
Tuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for...
SAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
TUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and...
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
SAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (βAptoseβ or the βCompanyβ) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.03 | -7.89473684211 | 0.38 | 0.44 | 0.3 | 87720 | 0.35177839 | CS |
4 | 0.105 | 42.8571428571 | 0.245 | 0.55 | 0.24 | 55722 | 0.35349939 | CS |
12 | -0.16 | -31.3725490196 | 0.51 | 0.58 | 0.19 | 34113 | 0.34811295 | CS |
26 | -0.67 | -65.6862745098 | 1.02 | 1.1 | 0.19 | 20067 | 0.4304819 | CS |
52 | -2.89 | -89.1975308642 | 3.24 | 3.48 | 0.19 | 13969 | 0.89641609 | CS |
156 | -26.5 | -98.696461825 | 26.85 | 29.25 | 0.19 | 16988 | 12.92986164 | CS |
260 | -103.6 | -99.6632996633 | 103.95 | 189.3 | 0.19 | 34648 | 76.28076741 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions